|Videos|June 5, 2020

Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?

Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.

Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.

The debate has been complicated in recent days, after The New England Journal of Medicine and The Lancet had authors issue retractions of articles based on a potentially faulty data source. The contested articles came from a database which cannot be verified. The results also showed what some view as an unrealistic level of harm from the drug, even among hydroxychloroquine skeptics.

A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.